 | • レポートコード：MRC2303G073 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、150ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：バイオ |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、世界のバイオプロセス技術市場規模が、予測期間中、CAGR 9.3％で増加すると推測されています。本書では、バイオプロセス技術の世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（器具、消耗品・付属品）分析、用途別（組換えタンパク質、モノクローナル抗体、抗生物質、その他）分析、エンドユーザー別（バイオ製薬会社、CMO（製造受薬機関）、学術研究機関、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、F. Hoffmann-La Roche Ltd、Sartorius Group、Thermo Fisher Scientific, Inc.、Agilent Technologies, Inc.、ELITechgroup Spa (Gonotec Gmbh)、Advanced Instruments, LLC、Danaher Corporationなどが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のバイオプロセス技術市場規模：製品別 - バイオプロセス技術器具の市場規模 - バイオプロセス技術消耗品・付属品の市場規模 ・世界のバイオプロセス技術市場規模：用途別 - 組換えタンパク質における市場規模 - モノクローナル抗体における市場規模 - 抗生物質における市場規模 - その他用途における市場規模 ・世界のバイオプロセス技術市場規模：エンドユーザー別 - バイオ製薬会社における市場規模 - CMO（製造受薬機関）における市場規模 - 学術研究機関における市場規模 - その他エンドユーザーにおける市場規模 ・世界のバイオプロセス技術市場規模：地域別 - 北米のバイオプロセス技術市場規模 アメリカのバイオプロセス技術市場規模 カナダのバイオプロセス技術市場規模 メキシコのバイオプロセス技術市場規模 … - ヨーロッパのバイオプロセス技術市場規模 ドイツのバイオプロセス技術市場規模 イギリスのバイオプロセス技術市場規模 フランスのバイオプロセス技術市場規模 … - アジア太平洋のバイオプロセス技術市場規模 中国のバイオプロセス技術市場規模 日本のバイオプロセス技術市場規模 インドのバイオプロセス技術市場規模 … - 南米/中東のバイオプロセス技術市場規模 ブラジルのバイオプロセス技術市場規模 アルゼンチンのバイオプロセス技術市場規模 サウジアラビアのバイオプロセス技術市場規模 ・競争状況 ・市場機会・将来動向 |
The bio-process technology market studied was projected to grow with a CAGR of nearly 9.3% over the forecast period.
The COVID-19 pandemic has substantially impacted various markets, so the bioprocess technology market faced tremendous disruptions in the initial phase. The COVID-19 outbreak affected the bioprocess technology market’s growth. However, this market is expected to gain traction due to the powerful urge to develop vaccines and other biological products. For instance, in 2021, Poznan University of Economics and Business published an article that biopharma companies undertook new partnerships to discover and deliver a new vaccine for COVID-19. The pandemic has also enabled the development of several innovative projects related to the COVID-19 vaccine and drug development. Bioprocess technology is highly adopted for vaccine and other biopharmaceutical production. Thus, the pandemic significantly impacted the bioprocess technology market.
The factors driving the growth of the studied market are expansion in the biopharmaceutical industry and increasing investments in research and development by biotechnology and pharmaceutical companies. The addition of biopharmaceutical companies is leading to the developing of new drugs and biologics products to address the unmet medical needs of patients suffering from various chronic and rare diseases. This has led to a rise in the usage of bioprocessing systems with better process efficiency and throughput, thereby contributing to the growth of the studied market.
In October 2022, Oculis SA and European Biotech Acquisition Corp reported they had entered into a definitive business combination agreement. This agreement is to accelerate the development of Oculis’ differentiated ophthalmology pipeline. This product addresses areas of significant medical need, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications, such as glaucoma, affecting growing patient populations. Thus, such agreements and partnerships between different biopharmaceutical companies for developing innovative products propel the studied market’s growth.
Furthermore, the increasing research and development are also contributing to the growth of the studied market. For instance, Thermo Fisher Scientific’s 2021 annual report reported that the company registered a research and development cost of USD 1,406.00 million in 2021, compared to USD 1,181.00 million in 2020. The R&D expenses grew by 19.05% in 2021. Similarly, in 2021, Becton Dickson and Company, in its 2021 annual report, reported that the company’s research and development expenses increased by 22.1% in the year 2021. Thus growing research and development expenses of biopharmaceutical companies are contributing to the development of innovative biopharma products, thereby driving the growth of this market.
Thus, the market is expected to witness significant growth over the forecast period due to the expansion in the biopharmaceutical industry and increasing investments in research and development by biotechnology and pharmaceutical companies. However, the high cost of instruments and strict regulations may slow down the growth over the studied period.
Bio-process Technology Market Trends
Recombinant Protein Segment is Expected to Witness a Significant Growth Over the Forecast Period.
The recombinant protein segment is expected to witness significant growth over the forecast period owing to the growing demand for recombinant proteins for therapeutic applications. Moreover, the recombinant therapeutic proteins provide essential therapies for various diseases, such as diabetes, cancer, infectious diseases, hemophilia, and anemia.
Furthermore, recombinant proteins are valuable tools in understanding protein-protein interactions, and the increasing research and development and technological advancements are also expected to drive the growth of this segment. For instance, in October 2022, Larimar Therapeutics, Inc. reported issuing a United States patent for the protection of CTI-1601. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich’s ataxia who cannot produce enough of this essential protein. Thus, such recombinant protein development is significantly driving this segment’s growth.
Similarly, in February 2021, Sanofi and GSK promulgated the initiation of a new randomized, double-blind, multi-center dose-finding Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine with 720 volunteers. Thus, innovation in healthcare solutions and developing of a new recombinant protein-based drug drive the segment’s growth.
Moreover, recombinant protein therapeutics offer highly effective treatments for illnesses like diabetes, cancer, infectious disorders, hemophilia, and anemia. The increasing prevalence of chronic diseases like diabetes also boosts the demand for recombinant proteins. For instance, in 2021, IDF reported that 537 million persons (20-79 years old) are estimated to have diabetes in the year 2021. This number is expected to increase by 643 million diabetics worldwide by 2030 and 783 million diabetes cases by 2045. Thus, with the increase in the diabetic population, the demand for recombinant proteins in the therapeutics segment is likely to show lucrative growth in the coming years, thereby contributing to the development of this segment.
Thus, due to the growing demand for recombinant proteins for therapeutic applications and new product launches, the segment is expected to witness significant growth over the forecast period.
North America is Expected to Witness a Significant Growth Over the Forecast Period.
North America is expected to witness significant growth over the forecast period owing to government support for promoting bioprocess technologies, rising medical expenditure, and developing healthcare infrastructure. In addition, the region has witnessed major collaborative activities with healthcare giants that are extensively investing in R&D in bioprocess technology development. For instance, in March 2022, Stam Biotech raised USD 17 million for its next-generation 3-D printer bioreactor.
Similarly, in May 2022, GOOD Meat, signed an exclusive multi-year agreement with ABEC, Inc. to design, manufacture, install and commission the largest known bioreactors for avian and mammalian cell culture. Technologies are focused on helping customers in the biopharmaceutical and pharmaceutical industry to improve the human condition and to provide life-changing drugs to market faster and more efficiently. The collaboration between the companies has leveraged their complementary strengths to develop specific workflows, which bridge the gap between analytical and process solutions.
Apart from that, major biopharmaceutical industry such as Thermo Fischer Scientific, Agilent Technologies, etc. is also driving the growth of the studied market in the region. These major biopharmaceutical companies are expanding and growing the biopharmaceutical segment in North America. For instance, in October 2021, 3M Health Care and Thermo Fisher Scientific collaborated to meet the growing demand for protein-based therapeutics, manufacturers need advanced technologies and solutions that support reliable and consistent manufacturing processes. The collaboration between 3M and Thermo Fisher has also enabled the manufacturers to capture high titer, high cell-density cultures to improve harvesting and clarification and optimize manufacturing capacity, quality, and efficiency.
Thus, the technologies, expansions, and investments by these global biopharmaceutical companies are driving the bioprocess technology market in North America.
Bio-process Technology Market Competitor Analysis
The bio-process technology market is fragmented and competitive due to many companies operating globally and regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known as F. Hoffmann-La Roche Ltd, Sartorius Group, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Elitechgroup Spa (Gonotec Gmbh), Advanced Instruments, LLC, Danaher Corporation, Merck KGaA, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Lonza Group AG and General Electric Co., Ltd (GE Healthcare Company).
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Expansion in the Biopharmaceutical Industry
4.2.2 Increasing Investments in Research and Development by Biotechnology and Pharmaceutical Companies
4.3 Market Restraints
4.3.1 High Cost of Instruments
4.3.2 Strict Regulations
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Product
5.1.1 Instruments
5.1.1.1 Bioprocess Analyzers
5.1.1.2 Osmometers
5.1.1.3 Bioreactors
5.1.1.4 Incubators
5.1.1.5 Other Instruments
5.1.2 Consumables and Accessories
5.1.2.1 Culture Media
5.1.2.2 Reagents
5.1.2.3 Other Consumables and Acessories
5.2 By Application
5.2.1 Recombinant Proteins
5.2.2 Monoclonal Antibodies
5.2.3 Antibiotics
5.2.4 Other Applications
5.3 By End-User
5.3.1 Biopharmaceutical Companies
5.3.2 Contract Manufacturing Organizations
5.3.3 Academic Research Institute
5.3.4 Other End-Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche Ltd
6.1.2 Sartorius Group
6.1.3 Thermo Fisher Scientific, Inc.
6.1.4 Agilent Technologies, Inc.
6.1.5 ELITechgroup Spa (Gonotec Gmbh)
6.1.6 Advanced Instruments, LLC
6.1.7 Danaher Corporation
6.1.8 Merck KGaA
6.1.9 Becton, Dickinson and Company
6.1.10 Bio-Rad Laboratories, Inc.
6.1.11 Lonza Group AG
6.1.12 General Electric Co., Ltd (GE Healthcare Company)
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
